Moderna Gets FDA Authorization of Booster Dose of Covid-19 Vaccine
November 19 2021 - 9:04AM
Dow Jones News
By Michael Dabaie
Moderna Inc. said the U.S. Food and Drug Administration extended
the emergency use authorization of a booster dose of its Covid-19
vaccine at the 50-microgram level to all adults aged 18 and older,
sending shares higher in premarket trade.
This booster can be used in all individuals 18 years and older
who have completed a primary vaccination with any other authorized
or approved Covid-19 vaccine, the company said.
Moderna shares rose 6% to $267.43 in premarket trade.
The booster dose is to be administered at least six months after
completion of any primary series Covid-19 vaccination.
In October, the FDA authorized for emergency use a booster dose
of Moderna's vaccine for people aged 65 and older, as well as
adults 18 to 64 at high risk of severe Covid-19 and people 18 to 64
with frequent institutional or occupational exposure to
SARS-CoV-2.
"This emergency use authorization comes at a critical time as we
enter the winter months and face increasing COVID-19 case counts
and hospitalizations across the country," said Chief Executive
Stephane Bancel.
In addition, Pfizer Inc. and BioNTech SE said Friday the FDA
expanded the emergency use authorization of a booster dose of the
their Covid-19 Vaccine to include individuals 18 years of age and
older.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 19, 2021 08:49 ET (13:49 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Sep 2023 to Sep 2024